Treatment for obesity
View Patent ↗The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.
1. A peptide having the amino acid sequence set forth in SEQ ID NO:1 wherein:
(i) residue 26 may be either asparagine or aspartic acid,
(ii) residue 29 may be either serine or alanine, and
(iii) residue 30 is asparagine or residue 32 is tyrosine.
2. The peptide of claim 1 , wherein 30 is asparagine and residue 32 is tyrosine.
3. The peptide of claim 1 , wherein residue 30 is asparagine.
4. The peptide of claim 1 , wherein residue 32 is tyrosine.
5. The peptide of claim 1 , wherein residue 30 is asparagine and residue 32 is tyrosine.
6. The peptide of claim 1 , wherein residue 26 is asparagine and residue 29 is serine.
7. The peptide of claim 3 , wherein residue 26 is asparagine and residue 29 is serine.
8. The peptide of claim 4 , wherein residue 26 is asparagine and residue 29 is serine.
9. The peptide of claim 5 , wherein residue 26 is asparagine and residue 29 is serine.
10. The peptide of claim 1 , wherein residue 27 is valine.
11. A peptide having the amino acid sequence set forth in SEQ ID NO:3.
12. A peptide having the amino acid sequence set forth in SEQ ID NO:4.
13. A peptide having the amino acid sequence set forth in SEQ ID NO:2 wherein:
(i) residue 25 may be either asparagine or aspartic acid,
(ii) residue 28 may be either serine or alanine, and
(iii) residue 29 is aparagine or residue 31 is tyrosine.
14. The peptide of claim 13 , wherein residue 29 is asparagine and residue 31 is tyrosine.
15. The peptide of claim 13 , wherein residue 29 is asparagine.
16. The peptide of claim 13 , wherein residue 31 is tyrosine.
17. The peptide of claim 13 , wherein residue 29 is asparagine and residue 31 is tyrosine.
18. The peptide of claim 13 , wherein residue 25 is asparagine and residue 28 is serine.
19. The peptide of claim 15 , wherein residue 25 is asparagine and residue 28 is serine.
20. The peptide of claim 16 , wherein residue 25 is asparagine and residue 28 is serine.
21. The peptide of claim 17 , wherein residue 25 is asparagine and residue 28 is serine.
22. The peptide of any of claim 13 , wherein residue 26 is valine.
23. A peptide having the amino acid sequence set forth in SEQ ID NO:5.
24. A peptide having the amino acid sequence set forth in SEQ ID NO:6.
25. A peptide having the amino acid sequence set forth in SEQ ID NO:7.
26. A peptide having the amino acid sequence set forth in SEQ ID NO:8.
27. A peptide having the amino acid sequence set forth in SEQ ID NO:12.
28. A peptide having the amino acid sequence set forth in SEQ ID NO:13.
29. A peptide having the amino acid sequence set forth in SEQ ID NO:14.
30. A pharmaceutical composition comprising the peptide of claim 29 and a pharmaceutically acceptable excipient, diluent or carrier.